A randomized controlled clinical trial of using inhaling Budesonide powder in treatment of cough variant asthma

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003395

Enrollment

Unknown

Registered

2013-07-20

Start date

2013-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cough variant asthma

Interventions

CVA-3 group:inhaled budesonide (400ug/day) for 3 months

CVA-6 group:inhaled budesonide (400ug/day) for 6 months

CVA-12 group:inhaled budesonide (400ug/day) for 12 months

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) the definite diagnosis of cough variant asthma patients; 2) the age of more than 18 and less 70 years old, gender is not limited; 3) have not used hormone drug before enter the trail; 4) voluntary signed informed consent.

Exclusion criteria

Exclusion criteria: 1) younger than 18 or older than 70; 2) companied with serious heart diseases, cerebrovascular diseases, liver diseases, kidney diseases, hematopoietic system diseases, mental illness; 3) combined chronic obstructive pulmonary disease patients; 4) has ever been used hormone; 5) caught acute upper respiratory tract infection during recent 2 weeks; 6) allergy to the drug; 7) participated in other clinical subjects within three months; 8) doctors think he can not suitable for the group's or other reasons.

Design outcomes

Primary

Measure	Time frame
IL-5 in induced sputum;IL-10 in induced sputum;EOS in induced sputum;PD20-FEV1.0;Cough score;	—

Secondary

Measure	Time frame
Bronchial provocation test;routine blood test;	—

Countries

China

Contacts

Public ContactXiaodong Chen

xdchen8@hotmail.com+86 18621865705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026